Furthermore, the administration of Mef2c-primed SVF or augmented CM-fated round cells in an animal model of heart failure is needed to investigate their safety (arrhythmogenicity) and efficacy (engraftment and improving ventricular function). The gene discussed is MEF2C; the disease is heart failure.